TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Inks Stiff Person Syndrome Clinical Trial Agreement with Mayo Clinic

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this year with an estimated 10 to 15 patients, some of whom may also suffer from type-1 diabetes; the initial focus of the study will be on the autoimmune disease Stiff Person Syndrome (“SPS”). According to the announcement, Adimune, which was created to lead Aditxt’s immune modulation therapeutic programs, has almost completed its preclinical package for the immunotherapy clinical study drug candidate ADI-100. The company noted that it has been working to launch ADI(TM)-100, its first immune modulation product candidate, for more than a year; the company has been targeting clinical trials to demonstrate its safety and indications of efficacy. “We are extremely pleased about having the opportunity to work with Mayo Clinic on trying to restore immune tolerance in patients suffering from devastating progressive autoimmune central nervous system disorders,” said Adimune co-CEO Dr. Joachim Friedrich Kapp in the press release. “The collaboration will include both preclinical and clinical studies and builds on Adimune’s current efforts to advance the full preclinical and clinical programs of ADI-100. We believe that the preclinical studies will help us to expand on the understanding of the technology, specifically the mechanism of action which induces antigen-specific immune tolerance without impairing the responsiveness of the immune system to fight infections and cancers.”

To view the full press release, visit https://ibn.fm/i3P1D

About Aditxt Inc.

Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which intends to offer personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork.